LUND, SE / ACCESSWIRE / May 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)
Spago Nanomedical’s annual report for 2023 is from today available at the company’s website, https://spagonanomedical.se/investor-relations/#financial-reports
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company.
Attachments
SOURCE: Spago Nanomedical
View the original press release on accesswire.com
SANTA CLARA, Calif., June 6, 2024 /PRNewswire/ -- Semler Scientific, Inc. (Nasdaq: SMLR), a pioneer…
The AI-powered symptom assessment and care navigation platform, which gives 50M+ users access to its…
The sports-tech innovator powered by 3X4 Genetics will work closely with OCSC coaching, training, and…
WALNUT CREEK, Calif., June 6, 2024 /PRNewswire/ -- RecoveryOne, a leading virtual musculoskeletal (MSK) care provider…
GROTON, Conn., June 6, 2024 /PRNewswire/ -- On February 26, 2024, Best Health Physical Therapy,…
MOUNTAIN VIEW, Calif., June 6, 2024 /PRNewswire/ -- NextSense is proud to announce that it…